科技 · 新闻详情
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
真正值得关注的不是这条新闻本身，而是它可能把「AI」的竞争焦点推向模型能力与产品控制权的竞争。
发生了什么：The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
为什么重要：AI 领域值得持续关注的动向。
观察窗口：接下来观察模型能力、产品入口和企业落地三条线是否同时推进。
正文来源：非原文：源网页正文只有单句或图片说明，以下为已有摘要与自动整理内容
原文链接：https://techcrunch.com/2026/09/23/enveda-secures-311m-to-bring-more-nature-derived-ai-drugs-into-clinical-trials/
原文链接：https://techcrunch.com/2026/09/23/enveda-secures-311m-to-bring-more-nature-derived-ai-drugs-into-clinical-trials/
The round valued the AI biotech at $2 billion.
It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
机器翻译/自动整理可能存在误差，请以原文为准。
继续阅读
正在加载推荐…